Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 35,000 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $8.57, for a total value of $299,950.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total value of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total value of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.98, for a total value of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.02, for a total value of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.57, for a total value of $185,465.00.

Clearside Biomedical, Inc. (CLSD) opened at 8.35 on Friday. The stock has a 50 day moving average price of $8.14 and a 200-day moving average price of $8.14. The firm’s market capitalization is $211.56 million. Clearside Biomedical, Inc. has a 52 week low of $6.50 and a 52 week high of $25.08.

Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.13). The business had revenue of $0.13 million during the quarter. Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. Analysts anticipate that Clearside Biomedical, Inc. will post ($2.10) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/clearside-biomedical-inc-clsd-director-sells-299950-00-in-stock/1617041.html.

CLSD has been the topic of a number of analyst reports. Zacks Investment Research lowered Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. ValuEngine upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Finally, Cowen and Company reissued a “buy” rating on shares of Clearside Biomedical in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Clearside Biomedical has a consensus rating of “Buy” and a consensus price target of $19.00.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace North America L.P. bought a new stake in shares of Clearside Biomedical in the first quarter worth about $1,720,000. Highbridge Capital Management LLC bought a new stake in shares of Clearside Biomedical in the first quarter worth about $217,000. Hillhouse Capital Management Ltd. grew its stake in shares of Clearside Biomedical by 5.3% in the second quarter. Hillhouse Capital Management Ltd. now owns 900,000 shares of the company’s stock worth $8,199,000 after purchasing an additional 45,100 shares during the last quarter. AWM Investment Company Inc. grew its stake in shares of Clearside Biomedical by 173.0% in the first quarter. AWM Investment Company Inc. now owns 341,217 shares of the company’s stock worth $2,709,000 after purchasing an additional 216,217 shares during the last quarter. Finally, Granite Investment Partners LLC grew its stake in shares of Clearside Biomedical by 74.8% in the second quarter. Granite Investment Partners LLC now owns 92,941 shares of the company’s stock worth $847,000 after purchasing an additional 39,765 shares during the last quarter. 52.45% of the stock is currently owned by institutional investors.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.